Irritable Bowel Syndrome (IBS) Treatment Market Forecast to 2028

1
Irritable Bowel Syndrome (IBS) Treatment Market
Irritable Bowel Syndrome (IBS) Treatment Market
Forecast to 2028 - COVID-19 Impact and Global
Analysis By Type IBS with Diarrhea (IBS-D), IBS
with Constipation (IBS-C), and Mixed IBS
(IBS-M), Product (Rifaximin, Eluxadoline,
Lubiprostone, Linaclotide, and Others), and
Distribution Channel (Hospital Pharmacies, Drug
Stores and Retail Pharmacies, and Online
Pharmacies)
2
Current and future Market Scenario
Irritable Bowel Syndrome (IBS) Treatment Market  
The Irritable Bowel Syndrome (IBS) Treatment
Market was valued at US 2,153.89 million in 2020
and is projected to reach US 4,600.30 million by
2028 it is expected to grow at a CAGR of 10.1
from 2021 to 2028.
3
Market Segments
Irritable Bowel Syndrome (IBS) Treatment Market  
By Distribution Channel (Hospital Pharmacies,
Drug Stores and Retail Pharmacies, and Online
Pharmacies)
By Product (Rifaximin, Eluxadoline,
Lubiprostone, Linaclotide, and Others)
By Type IBS with Diarrhea (IBS-D), IBS with
Constipation (IBS-C), and Mixed IBS (IBS-M)
4
Leading Players
Irritable Bowel Syndrome (IBS) Treatment Market

• Company Profiles in Irritable Bowel Syndrome
  (IBS) Treatment Market are
• Ironwood Pharmaceuticals, Inc.
• AbbVie.
• Sebela Pharmaceuticals, Inc.
• Takeda Pharmaceutical Company Limited
• Alfasigma S.p.A.
• Astellas Pharma Inc.
• AstraZeneca
• Synthetic Biologics, Inc.
• Bausch Lomb Incorporated
• Lannett Company Inc

5
Irritable Bowel Syndrome (IBS) Treatment
Market
Access Full Research Report at
https//www.theinsightpartners.com/reports/irritab
le-bowel-syndrome-treatment-market
Thank You!

• Thank You!